Cardiovascular Research Foundation announces late-breaking trials for TCT conference

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
 - Catheter-based therapy
Source: Abbott Vascular (formerly Evalve)

The Cardiovascular Research Foundation has announced the lineup of late-breaking clinical trials and first report investigations for the upcoming Transcatheter Cardiovascular Therapeutics (TCT) conference.

The conference is taking place from Oct. 29 to Nov. 2 at the Walter E. Washington convention center in Washington, D.C. Here are the late-breaking clinical trials and first report investigations:

Sunday, Oct. 30 – late-breaking clinical trials

9:00 a.m. – ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs. IVUS-Guided vs. Angio-Guided Stent Implantation in Patients with Coronary Artery Disease – presenter is Ziad A. Ali, MD, DPhil, an assistant professor of medicine at New York-Presbyterian/Columbia University Medical Center

9:20 a.m. – BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients with Coronary Artery Disease – presenter is Clemens von Birgelen, MD, PhD, a professor at Thoraxcentrum Twente in Enschede, The Netherlands

9:40 a.m. – BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs. a Zotarolimus-Eluting Stent in a More-Comers Population of Patients with Coronary Artery Disease – presenter is David E. Kandzari, MD, director of interventional cardiology research at the Piedmont Heart Institute in Atlanta

Sunday, Oct. 30 – first report investigations

12:15 p.m. – ABSORB China: Two-Year Clinical Outcomes from a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs. an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease – presenter is Runlin Gao, a professor at Fu Wai Hospital in Beijing, China

12:30 p.m. – ABSORB II: Three-Year Clinical Outcomes from a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs. an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease – presenter is Patrick W. Serruys, MD, PhD, a professor at Imperial College in London and the Thoraxcenter of Erasmus University in Rotterdam, The Netherlands

12:45 p.m. – LEADERS FREE: Two-Year Clinical and Subgroup Outcomes from a Prospective, Randomized Trial of a Polymer-Free Drug-Coated Stent and a Bare Metal Stent in Patients with Coronary Artery Disease at High Bleeding Risk – presenter is Philip M. Urban, MD, director of invasive cardiology at La Tour Hospital in Geneva, Switzerland

Monday, Oct. 31 – late-breaking clinical trials

9:00 a.m. – EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients with Left Main Coronary Artery Disease – presenter is Gregg W. Stone, MD, director of cardiovascular research and education at New York-Presbyterian Hospital/Columbia University Medical Center

9:15 a.m. – NOBLE: A Prospective, Randomized Trial Comparing Biolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients with Left Main Coronary Artery Disease – presenter is Evald H. Christiansen, MD, PhD, of Aarhus University Hospital in Denmark

Monday, Oct. 31 – first report investigations

12:00 p.m. – REVELUTION: 9-Month Clinical, Angiographic, IVUS, and OCT Outcomes with a Polymer-Free Sirolimus-Eluting Drug-Filled Stent – presenter is Stephen G. Worthley, MBBS, PhD, of GenesisCare Pty Ltd in Alexandria, Australia

12:13 p.m. – FANTOM II: 6-Month and 9-Month Clinical, Angiographic and OCT Results with a Radiopaque Desaminotyrosine Polycarbonate-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease – presenter is Alexandre Abizaid, MD, PhD, of Instituto Dante Pazzanese de Cardiologia in São Paulo, Brazil

12:21 p.m. – MeRes-1: 6-Month Clinical, Angiographic, IVUS and OCT Results with a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease – presenter is Ashok Seth, MBBS, of Fortis Escorts Heart Institute in New Delhi, India

12:29 p.m. – FORTITUDE: 9-Month Clinical, Angiographic, and OCT Results with an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease – presenter is Antonio Colombo, MD, director of the cardiac catheterization laboratory at Columbus Hospital/San Raffaele Hospital in Milan, Italy

12:37 p.m. – FUTURE-I: 6-Month Clinical, Angiographic, IVUS and OCT Results with a Thin-Strut